Investors in Professional

Sushi Venture Partners is an advisory and investment firm specializing in the media tech sector. Dedicated to supporting innovation in media technology, Sushi Venture Partners provides advisory services and strategic investments to companies aiming to transform the media landscape. They offer expertise in identifying emerging trends and opportunities within the media tech industry, fostering partnerships that drive growth and innovation. Sushi Venture Partners' commitment lies in leveraging their industry knowledge and network to empower entrepreneurs and businesses to achieve success and make impactful contributions to the media technology sector.

Greenbackers Investment Capital specializes in connecting disruptive technology providers with a network of climate-focused investors. As an investment firm, Greenbackers focuses on supporting startups and companies that offer innovative solutions to environmental and climate challenges. They facilitate investments that drive sustainable development and address pressing global issues through technology and innovation. Greenbackers Investment Capital's commitment lies in leveraging their network and expertise to accelerate the growth of climate-focused businesses and contribute to positive environmental impact.

Andurance Ventures is an independent technology venture capital firm based in London. Specializing in technology investments, Andurance Ventures focuses on identifying and supporting innovative startups with high growth potential. They provide strategic capital and operational support to help entrepreneurs scale their businesses and achieve market leadership. Andurance Ventures' commitment lies in fostering innovation and driving sustainable growth in the technology sector, leveraging their expertise and network to create value for both investors and portfolio companies.

Founded in 1999, Oxford Capital offers individuals and families access to some of the most innovative early-stage companies in the UK. Over the last 20 years, we have invested approximately £500 million in over 100 companies and have pioneered investing into early-stage companies via the Enterprise Investment Scheme. From our base in Oxford, one of the greatest knowledge clusters in the world, we invest across the UK and support early-stage companies to grow in international markets with the potential for rapid value growth. We invest in the future of UK technology in sectors such as ecommerce, fintech, digital health, and Artificial Intelligence. At the heart of our approach is backing the founders of these businesses, helping turn their vision into value and delivering returns to our investors.

MVM Life Science Partners, we are a specialized healthcare investment firm focused on early-stage and growth-stage companies in the life sciences sector. Founded in 1997 and headquartered in London, our firm invests globally in innovative biopharmaceuticals, medical technology, diagnostics, and digital health companies. Our approach combines deep sector expertise with strategic support to help our portfolio companies achieve their full potential. We have a strong track record of supporting groundbreaking therapies and technologies that make a significant impact on healthcare outcomes worldwide.

VentureFounders operates as an investment platform specializing in providing a highly curated and structured approach to investment opportunities. Focused on serving a High Net Worth (HNW) client base, VentureFounders offers access to exclusive investment opportunities across various sectors. Through rigorous due diligence and strategic selection, they aim to deliver attractive investment propositions that align with the financial objectives of their investor network. VentureFounders emphasizes transparency, quality, and alignment of interests to optimize investment outcomes for their clients.

Proxy Ventures is dedicated to helping startups succeed by providing strategic investments and amplifying their brand presence. As an investor, Proxy Ventures partners with early-stage companies to fuel their growth and development. Beyond financial backing, Proxy Ventures offers valuable expertise and support to accelerate the trajectory of startups, aiming to build strong, impactful brands that resonate in their respective markets.

Distill Ventures specializes in providing investment and strategic support to spirits entrepreneurs aiming to create global drinks brands. The firm collaborates closely with founders to accelerate the growth of their businesses through capital infusion, industry expertise, and operational guidance. Distill Ventures' approach is tailored to nurturing innovation in the spirits industry, fostering creativity and market expansion for emerging brands. With a global perspective and deep sector knowledge, Distill Ventures aims to partner with ambitious entrepreneurs to build the next generation of iconic drinks brands. For more details on their investment criteria and portfolio, please visit the Distill Ventures website.

Oakvale Capital is a prominent M&A (mergers and acquisitions) and strategic advisory boutique specializing in the gaming, gambling, and sports sectors. With a focused expertise in these industries, Oakvale Capital provides tailored advisory services to clients, ranging from startups to established companies and investors. Their services likely include advising on mergers, acquisitions, divestitures, strategic partnerships, and capital raising within the gaming, gambling, and sports sectors.

Zühlke is a global innovation partner. We turn big opportunities into working solutions that deliver ongoing value. For people, planet, and profit. A holistic growth partner to our clients, we close the gaps between strategic ambition, tech implementation, and operational excellence, helping you thrive in a business environment that's fluid, data-led, and collaborative. Together with clients and partners, our multidisciplinary teams deliver innovation and transformation initiatives in complex and regulated industries and ecosystems. Founded in Switzerland, Zühlke is a global team of 1,900 colleagues, with 17 locations in Europe and Asia.

Bridging the gap between disruptive discovery products and real-world patient reach, we identify high-potential compounds for in-licensing, we conduct clinical development and then select large pharmaceutical commercialization partners for out-licensing to maximize patient access across the globe. Through this specialized business model, Debiopharm can focus on the development of prescription drugs that target unmet medical needs in oncology and bacterial infections. Debiopharm is an independent biopharmaceutical company based in Switzerland with an ongoing commitment to develop tomorrow’s standard of care to cure cancer & infectious diseases and improve patient quality of life.

Rewired is an AI & Robotics investment vehicle backed by a private family office. We principally invest in applied science and technologies that advance machine perception. We believe that improving sensory capabilities will unlock the next-generation of smart robotics. To start, the group has committed $100 million to help develop technologies that enable robots to cope in the real world, make good decisions in real time, and help humans do more with less. We think that robotics should seamlessly complement humanity, not replace it. If you are developing a novel sensor system, a new approach to computer vision, a viable neural interface, or any other innovative technologies that help robots perceive and interact with the world, let's talk.